PEMBROBLAD: Real world effectiveness and safety of immune checkpoint inhibitors in patients with advanced urothelial carcinoma with histological variants.

被引：0
|
作者：
Amrane, Karim
Campedel, Luca
Bennamoun, Mostefa
Gabriel, Pierre-Etienne
Brouchet, Nicolas
Pouessel, Damien
Dugage, Matthieu Roulleaux
Thibault, Constance
Cancel, Mathilde
Gout, Mathilde
Flechon, Aude
Huillard, Olivier
Abbar, Baptiste
Borchiellini, Delphine
Doublet, Louis
Augusto-Pelegrin, Laetitia
Elouen, Boughalem
Moinard-Butot, Fabien
Dumont, Clement
Barthelemy, Philippe
机构：
[1] Oncol Dept, Morlaix, France
[2] CHU Clermont Ferrand, Clermont Ferrand, France
[3] Inst Mutualiste Montsouris, Paris, France
[4] Hop St Louis, Paris, France
[5] IUC Oncopole, Toulouse, France
[6] IUCT Oncopole, Inst Claudius Regaud, Toulouse, France
[7] Hop Europeen Georges Pompidou, Paris, France
[8] Univ Paris Cite, Hop Europeen Georges Pompidou, AP HP Ctr, Inst Canc Paris CARPEM,Dept Pharmacovigilance, Paris, France
[9] Univ Hosp, Dept Med Oncol, Tours, France
[10] Ctr Leon Berard, Lyon, France
[11] Univ Paris Cite, Inst Canc Paris CARPEM, Dept Med Oncol, Hop Cochin,AP HP Ctr, Paris, France
[12] Hop La Pitie Salpetriere, Paris, France
[13] Ctr Antoine Lacassagne, Nice, France
[14] Hop Prive Drome Ardeche, Valence, France
[15] CHU Rouen, Rouen, France
[16] Inst Cancerol Ouest, Angers, France
[17] ICANS Inst Cancerol Strasbourg Europe, Strasbourg, France
[18] APHP Hop St Louis, Paris, France
[19] Inst Cancerol Strasbourg Europe, Med Oncol, Strasbourg, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
261-566-9718-9794; 261-492-3532-2370-7650-2700; 261-492-2769; 613-135-244-3829; 283-9769-3573-426; 7; 3; 2; 242; 2018; 1; 38092-27449; 38092-31019; 38116-38094-8; 5;
D O I：
10.1200/JCO.2024.42.4_suppl.624
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：624 / 624
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of immune checkpoint inhibitors in older HCC patients: A real-world study
    Cheng, J.
    Chen, B.
    Lu, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S338 - S338
  • [42] A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors
    Khaki, Ali Raza
    Li, Ang
    Diamantopoulos, Leonidas N.
    Miller, Natalie J.
    Carril-Ajuria, Lucia
    Castellano, Daniel
    De Kouchkovsky, Ivan
    Koshkin, Vadim
    Park, Joseph
    Alva, Ajjai
    Bilen, Mehmet A.
    Stewart, Tyler
    Santos, Victor
    Agarwal, Neeraj
    Jain, Jayanshu
    Zakharia, Yousef
    Morales-Barrera, Rafael
    Devitt, Michael
    Nelson, Ariel
    Hoimes, Christopher J.
    Shreck, Evan
    Gartrell, Benjamin A.
    Sankin, Alex
    Tripathi, Abhishek
    Zakopoulou, Roubini
    Bamias, Aristotelis
    Rodriguez-Vida, Alejo
    Drakaki, Alexandra
    Liu, Sandy
    Kumar, Vivek
    Lythgoe, Mark P.
    Pinato, David J.
    Murgic, Jure
    Frobe, Ana
    Joshi, Monika
    Velho, Pedro Isaacsson
    Hahn, Noah
    Buznego, Lucia Alonso
    Duran, Ignacio
    Moses, Marcus
    Barata, Pedro
    Galsky, Matthew D.
    Sonpavde, Guru
    Yu, Evan Y.
    Shankaran, Veena
    Lyman, Gary H.
    Grivas, Petros
    EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (03): : 464 - 472
  • [43] Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis
    Ferro, Matteo
    Crocetto, Felice
    Tataru, Sabin
    Barone, Biagio
    Dolce, Pasquale
    Lucarelli, Giuseppe
    Sonpavde, Guru
    Musi, Gennaro
    Antonelli, Alessandro
    Veccia, Alessandro
    Terracciano, Daniela
    Busetto, Gian Maria
    Del Giudice, Francesco
    Marchioni, Michele
    Schips, Luigi
    Porpiglia, Francesco
    Fiori, Cristian
    Carrieri, Giuseppe
    Lasorsa, Francesco
    Verde, Antonio
    Scafuri, Luca
    Buonerba, Carlo
    Di Lorenzo, Giuseppe
    CLINICAL GENITOURINARY CANCER, 2023, 21 (05) : 574 - 583
  • [44] TERT promoter mutation as a prognostic marker in patients with advanced urothelial carcinoma treated with immune checkpoint inhibitors.
    de Kouchkovsky, Ivan
    Zhang Li
    Philip, Errol
    Wright, Francis
    Kim, Daniel Myung
    Natesan, Divya
    Kwon, Daniel
    Ho, Hansen
    Ho, Son
    Chan, Emily
    Porten, Sima P.
    Desai, Arpita
    Huang, Franklin W.
    Chou, Jonathan
    Oh, David Yoonsuk
    Pruthi, Raj
    Fong, Lawrence
    Small, Eric Jay
    Friedlander, Terence W.
    Koshkin, Vadim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [45] New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors
    Bamias, Aristotelis
    Merseburger, Axel
    Loriot, Yohann
    James, Nicholas
    Choy, Ernest
    Castellano, Daniel
    Lopez-Rios, F.
    Calabro, Fabio
    Kramer, Mario
    de Velasco, Guillermo
    Zakopoulou, Roubini
    Tzannis, Kimon
    Sternberg, Cora N.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (01)
  • [46] Outcomes with immune checkpoint inhibitors (ICI) in patients (pts) with MTAP alterations (alt) in advanced urothelial carcinoma (aUC).
    Talukder, Rafee
    Bakaloudi, Dimitra Rafailia
    Lin, Genevieve Ihsiu
    Enright, Tom
    Leary, Jacob Beck
    Makrakis, Dimitrios
    Tripathi, Nishita
    Agarwal, Neeraj
    Jindal, Tanya
    Koshkin, Vadim S.
    Brown, Jason R.
    Johnson, Jeffrey
    Zakharia, Yousef
    Park, Joseph J.
    Alva, Ajjai Shivaram
    Barrera, Rafael Morales
    Drakaki, Alexandra
    Barata, Pedro C.
    Khaki, Ali Raza
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors
    Martini, Dylan J.
    Shabto, Julie M.
    Goyal, Subir
    Liu, Yuan
    Olsen, T. Anders
    Evans, Sean T.
    Magod, Benjamin L.
    Ravindranathan, Deepak
    Brown, Jacqueline T.
    Yantorni, Lauren
    Russler, Greta Anne
    Caulfield, Sarah
    Goldman, Jamie M.
    Nazha, Bassel
    Joshi, Shreyas Subhash
    Kissick, Haydn T.
    Ogan, Kenneth E.
    Harris, Wayne B.
    Kucuk, Omer
    Carthon, Bradley C.
    Master, Viraj A.
    Bilen, Mehmet Asim
    ONCOLOGIST, 2021, 26 (12): : 1017 - 1025
  • [48] Genomic correlates of response and resistance to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC) in a real-world setting.
    Pramod, Nikhil
    Makarov, Vladimir
    Dawsey, Scott
    Pavicic, Paul G.
    Patgunarajah, Ubenthira
    Nair, Monica
    Ornstein, Moshe Chaim
    Gilligan, Timothy D.
    Wee, Christopher Eing
    Nizam, Amanda
    Mian, Omar Y.
    Nguyen, Jane
    Diaz-Montero, C. Marcela
    Gupta, Shilpa
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 670 - 670
  • [49] Repeat Treatment of Patients With Advanced Urothelial Carcinoma With Immune Checkpoint Inhibitors Following Prior Progression on a Checkpoint Inhibitor Regimen: A Case Series
    Jindal, Tanya
    Chou, Jonathan
    Friedlander, Terence
    Barata, Pedro C.
    Koshkin, Vadim S.
    CLINICAL GENITOURINARY CANCER, 2022, 20 (02) : 189 - 194
  • [50] Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia
    Al Nuhait, Mohammed
    Bajnaid, Eshtyag
    Al Otaibi, Abdulmalik
    Al Shammari, Abdullah
    Al Awlah, Yousef
    SCIENCE PROGRESS, 2021, 104 (01)
12345